The US Department of Defense (DoD) Prostate Cancer Research Program (PCRP), a division of its Congressionally Directed Medical Research Programs (CDMRP) released a program announcement for the FY16 Clinical Consortium Research Site Award. This award provides additional support to PCCTC sites to develop and enhance collaborations and resources necessary to rapidly execute their early phase prostate cancer clinical trials. The principal goal of the award is to combine the efforts of leading investigators to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of prostate cancer.
The PCRP Clinical Consortium Award mechanism was previously offered in FY05, FY06, FY08, and FY13. Overall, 57 Clinical Consortium Award applications have been received, and 35 have been recommended for funding. This year the PCRP is offering the Clinical Consortium Research Site Award mechanism to support the inclusion of Clinical Research Sites to the existing Prostate Cancer Clinical Trials Consortium (PCCTC).
The CDMRP expects to allot approximately $2.6M of the $80M FY16 PCRP appropriation to fund approximately eight Clinical Consortium Research Site Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program. The PCRP plans to invest $800,000 in direct costs (plus indirect costs) per Clinical Research Site over a 4-year period. A total of $200,000 in direct costs (plus indirect costs) will be allocated from the FY16 budget to fund the first year of performance for each Site.
The pre-application submission deadline is 5:00 p.m. Eastern time (ET), September 15, 2016. For more information on the funding opportunity please visit http://cdmrp.army.mil/funding/pcrp.shtml.